<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270307</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-CY-Russia</org_study_id>
    <nct_id>NCT02270307</nct_id>
  </id_info>
  <brief_title>MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis</brief_title>
  <acronym>MSC-CY</acronym>
  <official_title>Allogeneic Bone Marrow Transplantation (Allo-BMT) From Human Leukocyte Antigen (HLA) - Identical Related and Unrelated Donors in Patients With Hematological Malignancies With High Risk of Relapse Using Cyclophosphamide (CY) and Mesenchymal Stromal Cells (MSC) as aGVHD Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the effectiveness of the new protocol which replace the standard immunosuppressive
      therapy with use of MSCs and CY in patients at high risk of relapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial try to find a new way of refractory hematological malignancies treatment. Aim of
      this study evaluating the effectiveness of the new protocol which replace the standard
      immunosuppressive therapy with use of MSCs and CY in patients at high risk of relapse.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>MSC+CY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide 50 mg/kg/day at +3, +4 day once daily after BMT Mesenchymal stromal cells 1*10^6/kg at day of recovery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Dose 50 mg/kg at day +3,+4 once daily</description>
    <arm_group_label>MSC+CY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stromal cells</intervention_name>
    <description>Dose 1 million per kg, at day of recovery once</description>
    <arm_group_label>MSC+CY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory forms of acute leukemia, but in complete remission (CR)

          -  Second and third remission of acute leukemia

          -  2nd and 3rd chronic phase chronic myelogenous leukemia (CML) (or Ph + ALL)

          -  relapsed multiple myeloma

          -  advanced leukemia

        Exclusion Criteria:

          -  ICU

          -  Mechanical ventilation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valery Savchenko, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Netherlands: Ministry of Health, Welfare and Sports</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena N Parovichnikova, PhD,MD</last_name>
    <phone>+79161252623</phone>
    <email>elenap@blood.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mikhail Y Drokov, PhD,MD</last_name>
    <phone>+79261841813</phone>
    <email>mdrokov@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BMT department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Parovichnikova, Prof MD PhD</last_name>
      <phone>+79161487131</phone>
      <email>kuzlara@rambler.ru</email>
    </contact>
    <investigator>
      <last_name>Elena Parovichnikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>October 17, 2014</last_update_submitted>
  <last_update_submitted_qc>October 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Center for Hematology, Russia</investigator_affiliation>
    <investigator_full_name>Elena N.Parovichnikova</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

